Heteroaryl substituted pyrrolo[2,3-b]pyridines and...

Details Heteroaryl substituted pyrrolo[2,3-b]pyridines and... Heteroaryl substituted pyrrolo[2,3-b]pyridines and...

2006-12-12

2009-10-06

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S280000, C546S113000, C514S300000

Reexamination Certificate

active

07598257

ABSTRACT:
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

REFERENCES:
patent: 6335342 (2002-01-01), Longo et al.
patent: 6486322 (2002-11-01), Longo et al.
patent: 6579882 (2003-06-01), Stewart et al.
patent: 7005436 (2006-02-01), Lloyd et al.
patent: 2003/0165576 (2003-09-01), Fujii et al.
patent: 2004/0009983 (2004-01-01), Cox et al.
patent: 2004/0198737 (2004-10-01), Cox et al.
patent: 2005/0153989 (2005-07-01), Grotzfeld et al.
patent: 2006/0004010 (2006-01-01), Habashita et al.
patent: 2006/0106020 (2006-05-01), Rodgers et al.
patent: 2006/0183761 (2006-08-01), Ledeboer et al.
patent: 2006/0183906 (2006-08-01), Rodgers et al.
patent: 2007/0149506 (2007-06-01), Arvanitis et al.
patent: 2008/0188500 (2008-08-01), Arvanitis et al.
patent: 2008/0207584 (2008-08-01), Habashita et al.
patent: 2008/0312258 (2008-12-01), Rodgers et al.
patent: 2008/0312259 (2008-12-01), Rodgers et al.
patent: 30 36 390 (1982-05-01), None
patent: WO 97/02266 (1977-01-01), None
patent: WO 97/02262 (1997-01-01), None
patent: WO 97/02266 (1997-01-01), None
patent: WO 99/62908 (1999-12-01), None
patent: WO 99/65908 (1999-12-01), None
patent: WO 99/65909 (1999-12-01), None
patent: WO 01/42246 (2001-06-01), None
patent: WO 02/00661 (2002-01-01), None
patent: WO 02/055084 (2002-07-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 02/096909 (2002-12-01), None
patent: WO 03/011285 (2003-02-01), None
patent: WO 03/048162 (2003-06-01), None
patent: WO 2004/041814 (2004-05-01), None
patent: WO 2004/047843 (2004-06-01), None
patent: WO 2004/072063 (2004-08-01), None
patent: WO 2004/099204 (2004-11-01), None
patent: WO 2004/099205 (2004-11-01), None
patent: WO 2005/013986 (2005-02-01), None
patent: WO 2005/051393 (2005-06-01), None
patent: WO 2005/060972 (2005-07-01), None
patent: WO 2005/095400 (2005-10-01), None
patent: WO 2005/105146 (2005-11-01), None
patent: WO 2005/105814 (2005-11-01), None
patent: WO 2005/105988 (2005-11-01), None
patent: WO 2005/110410 (2005-11-01), None
patent: WO 2005/121130 (2005-12-01), None
patent: WO 2006/013114 (2006-02-01), None
patent: WO 2006/046023 (2006-05-01), None
patent: WO 2006/046024 (2006-05-01), None
patent: WO 2006/056399 (2006-06-01), None
patent: WO 2006/096270 (2006-09-01), None
patent: WO 2006/127587 (2006-11-01), None
patent: WO 2006/129199 (2006-12-01), None
patent: WO 2006/136823 (2006-12-01), None
patent: WO 2007/025090 (2007-03-01), None
patent: WO 2007/041130 (2007-04-01), None
patent: WO 2007/076423 (2007-07-01), None
patent: WO 2007/084557 (2007-07-01), None
patent: WO2007/117494 (2007-10-01), None
Bell, Malcolm, and Zalay, Andrew, “Synthesis of Substituted 3-Amino[6, 5-b] triazinoindoles.” Journal of Heterocyclic Chemistry, 12(5):1001-1004, Oct. 1975.
Fridman, Jordan et al. “Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders” poster presented at the American Society of Hematology, 49th Annual Meeting and Exposition, GA. Abstract #3538, poster #757, Dec. 10, 2007.
Gottlieb, A.B., et al, Nat Rev Drug Disc., 2008, 4:19-34.
Pirard, B. et al. J. Chem. Inf. Comput. Sci. 2000, 40, 1431-1440.
Verstovsek, S. et al. INCB18424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patient with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF), presentation at the American Society of Hematology 49thAnnual Meeting and Exposition, Dec. 10, 2007.
Verstovsek, S. et al. “The selective Janus kinase (JAK) inhibitor, INCB018424, shows efficacy in phase I/II trial in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)” Abstract #0444, presented Saturday, Jun. 14, 2008 at the European Hematology Association, 13thCongress, Jun. 12-15, Copenhagen, Denmark.
Fridman, J. et al. “Selective JAK Inhibition is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support” Abstract #0956, presented Sunday, Jun. 15, 2008 at the European Hematology Association, 13thCongress, Jun. 12-15, Copenhagen, Denmark.
Adv Pharmacol. 2000;47:113-74 , C. Schindler.
Agents Actions. Jan. 1993;38(1-2):116-21 , R. Roudebush.
Blume-Jensen P et al, Nature 2001, 411(6835):355-365.
Bolen JB. Nonreceptor tyrosine protein kinases. Oncogene. 1993, 8(8):2025-31.
Boudny, V., and Kovarik, J., Neoplasm. 49:349-355, 2002.
Bowman, T., et al. Oncogene 19:2474-2488, 2000.
Burger, R., et al. Hematol J. 2:42-53, 2001.
Candotti, F., L. Notarangelo, et al. (2002). “Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.” J Clin Invest 109(10): 1261-9.
Candotti, F., S. A. Oakes, et al. (1997). “Structural and functional basis for JAK3-deficient severe combined immunodeficiency.” Blood 90(10): 3996-4003.
Cetkovic-Cvrlje, M., A. L. Dragt, et al. (2003). “Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice.” Clin Immunol 106(3): 213-25.
De Vos, J., M. Jourdan, et al. (2000). “JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.” Br J Haematol 109(4):823-8.
Dudley, A.C. et al. Biochem. J. 2005, 390(Pt 2):427-36.
E. Quesada et al, Tetrahedron, 62 (2006) 6673-6680.
Immunol Today. Jan. 1998;19(1):37-44 , S. Grabbe.
Itagaki, Noriaki; Kimura, Mari; Sugahara, Tsutomu; Iwabuchi, Yoshiharu. (Organic Letters 2005; 7(19); 4181-4183.
James, C., et al. Nature 434:1144-1148, (2005).
Journal of Pharmaceutical Science, 66, 2 (1977), S. Berger.
Kawamura, M., D. W. McVicar, et al. (1994). “Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes.” Proc Natl Acad Sci U S A 91(14): 6374-8).
Levine, et al., Cancer Cell, vol. 7, 2005: 387-397.
Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem. 2004, 37(7):618-35.
Manning, G. et al., Science. 2002, 298(5600):1912-1934.
Neubauer, H., A. Cumano, et al. (1998). Cell 93(3): 397-409.
Ortmann, R. A., T. Cheng, et al. (2000). “Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation.” Arthritis Res 2(1): 16-32.
Parganas, E., D. Wang, et al. (1998). Cell 93(3): 385-95.
Park et al., Analytical Biochemistry 1999, 269, 94-104.
Pernis, A. B. and P. B. Rothman (2002). “JAK-STAT signaling in asthma.” J Clin Invest 109(10): 1279-83.
Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418.
Rodig, S. J., M. A. Meraz, et al. (1998). “Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.” Cell 93(3): 373-83.
Saemann, M. D., C. Diakos, et al. (2003). “Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3.” Am J Transplant 3(11): 1341-9.
Scott, M. J., C. J. Godshall, et al. (2002). “Jaks, STATs, Cytokines, and Sepsis.” Clin Diagn Lab Immunol 9(6): 1153-9.
Seto, Y., H. Nakajima, et al. (2003). “Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice.” J Immunol 170(2): 1077-83.
Sriram, K. et al. J. Biol. Chem. 2004, 279(19):19936-47. Epub Mar. 2, 2004.
Takemoto, S., J. C. Mulloy, et al. (1997). “Proliferation of adult T cell leukemia/lymphoma cells is ass

Affiliated with

Also associated with

Rating

Heteroaryl substituted pyrrolo[2,3-b]pyridines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heteroaryl substituted pyrrolo[2,3-b]pyridines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl substituted pyrrolo[2,3-b]pyridines and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4142742